Sight Sciences releases results of two-year multicenter ROMEO study
May 23rd 2023According to the company, study results show sustained reductions in both IOP and glaucoma medication use in mild-moderate primary open angle glaucoma patients treated with a procedure enabled with the OMNI Surgical System technology.
ASGCT 2023: Abeona Therapeutics announces preclinical data from its AAV ophthalmology program
May 18th 2023During the 26th annual meeting of the American Society of Gene & Cell Therapy, taking place through Saturday in Los Angeles, California, the company is delivering several presentations highlighting its AAV capsids and gene constructs.
Current status of corneal crosslinking, emerging treatment options
May 18th 2023In a presentation at the American Society of Cataract and Refractive Surgery meeting in San Diego, Kenneth A. Beckman, MD, FACS, discussed the current status of corneal crosslinking with some emerging treatments, including epi-on crosslinking.
Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial
May 17th 2023Diana V. Do, MD, presented details of the PHOTON study at the Association for Research in Vision and Ophthalmology annual meeting, held recently in New Orleans, highlighting the safety and efficacy of 8 milligrams of aflibercept.
A dangerous eye infection from EzriCare eye drops, months before the CDC’s warning
May 16th 2023In November 2022, doctors in Cleveland diagnosed a patient with a corneal ulcer with a Pseudomona aeruginosa infection. The patient acquired the infection from tainted EzriCare eye drops months before the CDC’s February 2023 warning.